NEW YORK–(COMMERCIAL THREAD) –WHY: New York, NY, October 9, 2021. Rosen Law Firm, a global investor rights law firm, reminds buyers of PolarityTE, Inc. (NASDAQ: PTE) securities between April 30, 2020 and August 23, 2020 2021 inclusive (the “Class Period”), of the important 23 November 2021 lead applicant time limit.
SO WHAT: If you purchased PolarityTE securities during the Class Period, you may be entitled to compensation without payment of any fees or additional charges through a contingency fee agreement.
WHAT TO DO NEXT: To join the PolarityTE class action lawsuit, go to http://www.rosenlegal.com/cases-register-2163.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action. A class action has already been filed. If you wish to act as the principal applicant, you must apply to the Court no later than November 23, 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies issuing reviews do not have significant experience, resources or recognition by their peers. Be wise in choosing the right lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was appointed by law360 as the Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants throughout the litigation period made false and / or misleading statements and / or failed to disclose that: (1) the application for an investigational new drug for SkinTE, a tissue product allegedly used to repair, reconstruct, replace and supplement skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision or removal of dysfunctional skin grafts, as well as contract research services (the “SkinTE IND”), was deficient in certain Chemistry, Manufacturing and Control Items (CMCs); (2) as a result, the United States Food and Drug Administration (“FDA”) was unlikely to approve SkinTE IND in its current form; (3) as a result, the Company significantly overestimated the likelihood of SkinTE IND obtaining FDA approval; and (4) accordingly, the Company’s public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.
To join the PolarityTE class action lawsuit, go to http://www.rosenlegal.com/cases-register-2163.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action.
No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future payback does not depend on whether he is a principal applicant.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.